Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1847 results
September 2015
-
Story Patient Perspectives
Putting patients first
Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.
-
Press release
Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients Retrospective contact tracing of former leprosy… -
Press release
Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma
Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak… -
Press release
Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States
Launch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here: Holzkirchen,… -
Press release
Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia
Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder,… -
Press release
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan… -
Press release
Novartis setzt sich weiter für die endgültige Ausrottung von Lepra ein
Die Vereinbarung für die kommenden fünf Jahre umfasst Spenden von Behandlungseinheiten im Wert von mehr als USD 40 Millionen, mit denen rund 1,3 Millionen Patienten geholfen werden… -
Press release
Novartis renouvelle son engagement à l'approche de la dernière ligne droite dans la lutte visant à éradiquer la lèpre
Ce nouvel engagement sur cinq ans comprend un don de médicaments d'une valeur estimée à plus d'USD 40 millions qui devrait permettre de traiter environ 1,3 million de patients Le nouveau… -
Press release
Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma
Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers…
August 2015
-
Press release
Novartis continues commitment to go the last mile in effort to eliminate leprosy
New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact… -
Press release
Das Novartis International BioCamp zeigt, wie Zusammenarbeit und Vielfalt Innovationen fördern, und inspiriert künftige wissenschaftliche Führungskräfte
Das International Biotechnology Leadership Camp (BioCamp) fördert das Interesse von Studierenden für wissenschaftlichen Fortschritt und unternehmerische Chancen Anlässlich des interaktiven Programms… -
Press release
Le Novartis International BioCamp souligne le rôle de la collaboration et de la diversité pour stimuler l'innovation et inspirer les futurs leaders scientifiques.
L'International Biotechnology Leadership Camp (BioCamp) mobilise des étudiants autour d'avancées scientifiques et d'opportunités entrepreneuriales. Ce programme interactif a réuni au siège de…